BGI Genomics Co Ltd banner

BGI Genomics Co Ltd
SZSE:300676

Watchlist Manager
BGI Genomics Co Ltd Logo
BGI Genomics Co Ltd
SZSE:300676
Watchlist
Price: 49.23 CNY 1.21% Market Closed
Market Cap: ¥20.6B

Relative Value

The Relative Value of one BGI Genomics Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 49.23 CNY, BGI Genomics Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BGI Genomics Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
BGI Genomics Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
BGI Genomics Co Ltd
SZSE:300676
20.6B CNY 5.5 -25.7 -20.6 -20.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
402.2B USD 6.7 171.3 16.6 23.5
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD 462 374.5 -2 631.9 -2 389.6 -2 389.6
US
Amgen Inc
NASDAQ:AMGN
206.8B USD 5.6 26.9 15.3 15.3
US
Gilead Sciences Inc
NASDAQ:GILD
182.9B USD 6.2 21.5 14.6 14.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.6B USD 10.2 31.1 23.8 24.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.3B USD 5.8 18.5 14 15.9
NL
argenx SE
XBRU:ARGX
43.3B EUR 14.3 33.5 57.4 59
AU
CSL Ltd
ASX:CSL
70.2B AUD 3.2 16.6 11.4 14.2
P/S Multiple
Revenue Growth P/S to Growth
CN
BGI Genomics Co Ltd
SZSE:300676
Average P/S: 3 105 036
5.5
5%
1.1
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
10%
0.7
US
Astria Therapeutics Inc
NASDAQ:ATXS
462 374.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.6
3%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
6.2
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
10%
0.6
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
P/E Multiple
Earnings Growth PEG
CN
BGI Genomics Co Ltd
SZSE:300676
Average P/E: 45.6
Negative Multiple: -25.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.3
89%
1.9
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 631.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.9
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.5
14%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
NL
argenx SE
XBRU:ARGX
33.5
42%
0.8
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
BGI Genomics Co Ltd
SZSE:300676
Average EV/EBITDA: 21.9
Negative Multiple: -20.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 389.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.3
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
18%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
15%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14
23%
0.6
NL
argenx SE
XBRU:ARGX
57.4
810%
0.1
AU
CSL Ltd
ASX:CSL
11.4
8%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
BGI Genomics Co Ltd
SZSE:300676
Average EV/EBIT: 23.9
Negative Multiple: -20.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 389.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.3
2%
7.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
21%
0.8
NL
argenx SE
XBRU:ARGX
59
N/A N/A
AU
CSL Ltd
ASX:CSL
14.2
11%
1.3
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett